Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe parkinsonian's patients

被引:0
作者
Vaamonde, J [1 ]
Ibàñez, R [1 ]
Gudin, M [1 ]
Hernández, A [1 ]
机构
[1] Complejo Hosp Ciudad Real, Serv Neurol, Ciudad Real 13002, Spain
来源
NEUROLOGIA | 2003年 / 18卷 / 03期
关键词
Parkinson's disease; severity; motor complications;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Daily fluctuations of motor performance and dyskinesias in patients with Parkinson's disease (PD) treated with levodopa represent a difficult challenge to our understanding. We report 10 patients diagnosed of severe PD (Hoehn and Yahr: III-IV/V) treated with levodopa (range of dose: 750-900 mg/day) in single drug therapy since their diagnosis (mean time of levodopatherapy: 4.8 +/- 2.4 months, range: 3-6 months). All patients developed motor complications within weeks to months after initiating L-dopatherapy. Two patients received an intravenous apomorphine infusion (mean dose: 8.5 mg/day) during a mean time of 7.5 hours, but motor complications persisted during the infusion in spite of continuous dopaminergic stimulus. The degree of nigrostriatal damage (disease severity) seems to be a very important risk factor for the development of treatment-related motor complications.
引用
收藏
页码:162 / 165
页数:4
相关论文
共 22 条
[1]   CHRONIC TREATMENT WITH L-DOPA, BUT NOT BROMOCRIPTINE INDUCES DYSKINESIA IN MPTP-PARKINSONIAN MONKEYS - CORRELATION WITH [H-3] SPIPERONE BINDING [J].
BEDARD, PJ ;
DIPAOLO, T ;
FALARDEAU, P ;
BOUCHER, R .
BRAIN RESEARCH, 1986, 379 (02) :294-299
[2]  
de la Fuente-Fernández R, 2001, ANN NEUROL, V49, P298
[3]   Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct:: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan [J].
Fox, SH ;
Henry, B ;
Hill, MP ;
Peggs, D ;
Crossman, AR ;
Brotchie, JM .
MOVEMENT DISORDERS, 2001, 16 (04) :642-650
[4]  
Frey KA, 2001, ANN NEUROL, V49, P285
[5]   A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease [J].
Korczyn, AD ;
Brunt, ER ;
Larsen, JP ;
Nagy, Z ;
Poewe, WH ;
Ruggieri, S .
NEUROLOGY, 1999, 53 (02) :364-370
[6]   SUSTAINED BROMOCRIPTINE THERAPY IN PREVIOUSLY UNTREATED PATIENTS WITH PARKINSONS-DISEASE [J].
LEES, AJ ;
STERN, GM .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1981, 44 (11) :1020-1023
[7]   Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus) [J].
Maratos, EC ;
Jackson, MJ ;
Pearce, RKB ;
Jenner, P .
MOVEMENT DISORDERS, 2001, 16 (04) :631-641
[8]  
Marsden C.D., 1982, Movement Disorders, V2, P96
[9]  
MIZUNO Y, 1995, NEUROLOGY, V45, P13
[10]   MOTOR FLUCTUATIONS IN PARKINSONS-DISEASE - PATHOGENETIC AND THERAPEUTIC STUDIES [J].
MOURADIAN, MM ;
JUNCOS, JL ;
FABBRINI, G ;
CHASE, TN .
ANNALS OF NEUROLOGY, 1987, 22 (04) :475-479